csirt@kutim:~/threat-intel/cve/CVE-2021-1449

Katalog CVE

CVSS 6.7 · Medium EPSS 0,27%

Kerentanan Improper Access Control pada cisco aironet access point software, cisco catalyst 9800 firmware +1 lainnya. Skor CVSS 3.1 6.7 (Medium) menurut NVD.

Deskripsi (NVD)

A vulnerability in the boot logic of Cisco Access Points Software could allow an authenticated, local attacker to execute unsigned code at boot time. The vulnerability is due to an improper check that is performed by the area of code that manages system startup processes. An attacker could exploit this vulnerability by modifying a specific file that is stored on the system, which would allow the attacker to bypass existing protections. A successful exploit could allow the attacker to execute unsigned code at boot time and bypass the software image verification check part of the secure boot process of an affected device. Note: To exploit this vulnerability, the attacker would need to have access to the development shell (devshell) on the device.

Rincian

Terbit di NVD
24 Maret 2021
Terakhir diubah
17 Juni 2026
Status NVD
Modified
CVSS 3.1
6.7 (Medium), sumber NVD
CVSS:3.1/AV:L/AC:L/PR:H/UI:N/S:U/C:H/I:H/A:H · uraikan di kalkulator
Jenis kelemahan (CWE)
CWE-284: Improper Access Control
EPSS (30 hari)
0,27% peluang dieksploitasi; lebih tinggi dari 18,4% CVE lain

Produk dan versi terdampak

VendorProdukVersi terdampak
cisco aironet access point software Semua versi
cisco catalyst 9800 firmware Semua versi sebelum 16.12.5
cisco catalyst 9800 firmware Versi 17.1 hingga sebelum 17.3.3
cisco catalyst 9800 firmware Versi 17.4 hingga sebelum 17.5.1
cisco wireless lan controller software Semua versi sebelum 8.5.171.0
cisco wireless lan controller software Versi 8.6 hingga sebelum 8.10.150.0

> Data dari konfigurasi CPE di NVD.

Referensi dan perbaikan

Sumber: NVD · CVE.org · EPSS. Halaman ini disusun otomatis dari data tersebut; pembaruan terakhir 5 Okt 2026, 20:10 WITA. Kalau sistem di Perangkat Daerah memakai produk ini dan butuh bantuan, laporkan lewat kanal pelaporan.